A practice deciding between exosome material and platelet-rich plasma for facial work is usually asking two questions at once. The first is which material the literature supports, and the second is what the procedure around it is allowed to do, because both are applied through the same microchannels and those channels are governed by device clearance and state scope rules rather than by the material.
This article takes the two questions in order. It sets out the one head-to-head trial in facial skin, describes how each material is prepared and what that costs in chair time, and then spends most of its length on depth, on the patient histories that change the calculation, and on the state rules that cap what a device may be set to do.
Regulatory position, stated once
There are no FDA-approved exosome products, and ExaVeyra supplies exosome material for research use only, described by its available formats and never by a dose. A microneedling device cleared under 21 CFR 878.4430 is cleared to create microchannels in skin; that clearance does not extend to delivering any product through them. PRP prepared and returned to the same patient in the same procedure is a separate regulatory matter that turns on the same surgical procedure exception at 21 CFR 1271.15(b). Which material a practitioner selects, at what depth, and for which patient are practitioner decisions that this article does not make.
One trial has compared the two materials on the same face
Estupiñan, Ly and Goldberg published an investigator-blinded, split-face, non-inferiority trial in the Journal of Cosmetic Dermatology in 2025. Participants with mild to moderate photoaging received three radiofrequency microneedling sessions, with PRP applied to one half of the face and topical adipose-derived exosome material to the other.
The authors reported that both halves improved comparably in wrinkling, dyschromia, erythema, texture and overall appearance, and that histology showed increased collagen I and glycosaminoglycans with no significant difference between arms. They noted in their introduction that no prior trial had compared the two in aesthetic dermatology.
A split-face design controls for the variables that usually confound facial studies, since age, sun history, skin type and adherence are identical on both halves. The design also has a known ceiling: with both halves needled by the same device in the same session, the trial compares what was applied afterward rather than the procedures themselves.
The authors described the exosome arm as an alternative that may suit needle-averse patients and can shorten the visit, since phlebotomy and centrifugation are not required.
That conclusion is an operational observation rather than a claim of superiority, and it is the honest read of a non-inferiority result. A practice weighing the two is choosing between comparable reported outcomes in one trial and two genuinely different workflows.
The two materials reach the treatment room by different routes
PRP is autologous. It is drawn from the patient at the visit, centrifuged in the office, and returned to that same patient in the same procedure, which is the pathway the FDA addresses in its guidance on the same surgical procedure exception under 21 CFR 1271.15(b).
Exosome material is allogeneic and arrives as a manufactured preparation with a certificate of analysis, a cold-chain history and defined available formats. The supply question moves from the centrifuge to the supplier, and what can be verified about a lot before it reaches the face becomes a document review rather than a bench procedure.
| Consideration | Platelet-rich plasma | Exosome material |
|---|---|---|
| Origin | Autologous, drawn at the visit | Allogeneic, manufactured and shipped |
| Preparation | Phlebotomy plus in-office centrifugation | Reconstitution or thaw per supplier instructions |
| Chair time added | Draw, spin and separation before application | Preparation only |
| Batch consistency | Varies with the patient, the draw, the kit and the spin protocol | Defined per lot by the manufacturer’s certificate of analysis |
| What the practice verifies | Kit, spin protocol, platelet yield | Certificate of analysis, characterisation panel, cold chain |
| US regulatory frame | Turns on the same surgical procedure exception at 21 CFR 1271.15(b) | No FDA-approved exosome product exists; supplied for research use |
| Evidence base in facial skin | Multiple randomised trials, pooled in meta-analyses and an overview of systematic reviews | Split-face trials and systematic reviews, with one head-to-head comparison |
The variability row is the one practitioners underweight. A PRP preparation is defined by the patient it came from and by the kit and spin protocol used to make it, so two practices running the same protocol on the same patient can produce different products.
Cruciani and colleagues made that point structurally in Blood Transfusion in 2024, in an overview of systematic reviews of PRP for facial rejuvenation. Their reading of the pooled literature turned substantially on heterogeneity in how the preparations were made and described.
The PRP literature is broader, and it is pooled
Chen and Zhou published a meta-analysis of PRP in skin aging covering randomised trials to December 2024, including nine trials and 358 patients. They reported improvement in subjective patient satisfaction with a risk ratio of 1.34 (95% CI 1.07 to 1.67) and in objective efficacy with a risk ratio of 1.42 (95% CI 1.01 to 2.00).
The same analysis reported no significant difference in adverse effects between PRP and control arms, with a risk ratio of 1.21 and a confidence interval from 0.50 to 2.92. The width of that interval is the honest signal: the pooled safety comparison is compatible with a range of effects rather than resolved.
Rodríguez-Castro and colleagues published a systematic review in 2025 that included nine clinical trials and two observational studies, and reported improvement in wrinkles and skin texture in four of them. Sollitto and colleagues narrowed to the periorbital region in 2025 and compared PRP against platelet-rich fibrin across fourteen studies.
What the pooled estimates support
Across these reviews the pooled estimates point in a consistent direction while the underlying trials differ in preparation method, injection or topical route, session count and interval. That combination is what makes PRP well studied and still difficult to standardise between practices.
The exosome literature is younger and built on split-face designs
Park and colleagues ran a 12-week prospective, randomised, split-face study in 2023 in 28 participants, pairing microneedling with an adipose tissue stem cell-derived exosome-containing solution on one side and microneedling with saline on the other, across three sessions at three-week intervals.
They reported a significantly higher Global Aesthetic Improvement Scale score on the treated side at final follow-up (p = 0.005), with instrument measurements of wrinkles, elasticity, hydration and pigmentation moving in the same direction, histopathology consistent with the clinical findings, and no serious adverse events.
That design is worth reading closely, because the control side received microneedling with saline. The comparison it supports is the addition of the solution to a needling session rather than the solution on its own, which is also how the material is applied in practice.
Two systematic reviews published since organise the wider field. Alzahrani and colleagues reviewed exosomes in skin rejuvenation in Dermatology Practical and Conceptual in 2026, and Jafarzadeh and colleagues reviewed extracellular vesicles and conditioned media for skin lightening and rejuvenation in Stem Cell Research and Therapy in 2025.
Where to start reading
Contreras and colleagues reviewed extracellular vesicles in regenerative and cosmetic medicine in the International Journal of Molecular Sciences in 2026, covering safety, clinical effectiveness and regulatory considerations together. A review that treats the regulatory question as part of the science is the more useful starting point for a practice, because the two arrive at the treatment room at the same time.
Depth is the variable that decides both safety and scope
Microneedling for either material targets the dermis. The channels have to reach viable dermal tissue for the wound-healing response the literature studies, and they have to stop before the subcutaneous plane, where the tissue is fat and vasculature rather than the collagen-bearing matrix the procedure is aimed at.
Facial dermis gives less room for that than practitioners expect. Chopra and colleagues measured topographic skin thickness across the face in Aesthetic Surgery Journal in 2015 and reported the thickest dermis at the lower nasal sidewall at roughly 1,969 micrometres and the thinnest at the upper medial eyelid at roughly 759 micrometres.
Jeong and colleagues measured facial skin ultrasonographically in Skin Research and Technology in 2023 and reported regional variation with age, site, sex and body mass index. Both papers describe the same practical fact: one depth setting is not one anatomical result across a face.
What the numbers mean at the cartridge
A 1.5 mm setting sits comfortably within dermis on a cheek or a forehead and exceeds the full measured thickness of upper medial eyelid skin by roughly a factor of two. The periorbita, the temple, the nasal ala and the vermilion border are the regions where a setting chosen for the mid-face stops being a dermal setting. Region-by-region adjustment is a practitioner judgement, and the anatomy papers above are the reference for it.
Crossing into subcutaneous tissue changes three things at once. It moves the procedure away from the plane the microneedling literature studied, it introduces vascular and nerve structures the dermal plane does not contain, and it moves the act closer to the definitions that state boards and the FDA use to separate a device procedure from an injection.
Gowda and colleagues published a systematic review of potential adverse effects of microneedling in the Journal of Clinical and Aesthetic Dermatology in 2021, and it is the reference worth having on file before a facial programme launches rather than after a complication.
Injection is where the reported exosome harms occurred
Two 2025 papers in the Journal of Cosmetic Dermatology describe what happened when exosome-containing formulations were injected rather than applied. AlBargawi reported ischemic necrosis in a 38-year-old man three days after multiple intradermal injections of a lyophilized exosome product, with ulcerated papules and dusky discoloration on both cheeks.
The eschars sloughed at two weeks without secondary infection, and the patient was left with atrophic scarring and hyperpigmentation that three laser sessions improved only modestly. The author framed the case as an underreported complication of unapproved injectable exosome products.
Park reported a case series of four adult women who developed persistent erythema, nodules, granulomatous inflammation and scarring after intradermal administration of exosome-containing products in a nonclinical setting. All four had incomplete resolution and residual scarring despite corticosteroids, laser and surgical removal.
Both papers describe products injected into the dermis. The trials that report favourable facial outcomes describe material applied to the skin surface after channels were created.
That distinction is the practical centre of this article. A topical-after-needling workflow keeps the material on the surface and the depth decision with the device, where it can be set, documented and audited against a state rule and a clearance.
State rules set the ceiling your device settings have to respect
The federal layer is the simpler of the two. The FDA classified the microneedling device for aesthetic use as Class II under 21 CFR 878.4430, product code QAI, and published guidance in November 2020 on when a microneedling product is a device at all, under docket FDA-2017-D-4792.
State law is where the ceiling actually sits, because it decides who may hold the handpiece. The rules sort into four recognisable tiers, and a practice can usually place its own state in one of them before calling the board to confirm the detail.
| Tier | How the rule reads | Named example |
|---|---|---|
| Microneedling is outside cosmetology entirely | The board defines microneedling by depth and places the whole procedure beyond the licence | Florida Rule 61G5-18.00015 defines it as creating microchannels 0.25 to 2.5 mm deep and treats skin perforation as a bodily intrusion outside cosmetology scope |
| No skin penetration at any depth | The cosmetology board prohibits puncturing skin, so there is no permitted setting | California, where the Board of Barbering and Cosmetology treats skin penetration as outside esthetician scope |
| Permitted to a stated depth by an advanced licence | A master-level licence carries an explicit millimetre ceiling above which supervision is required | Utah Admin Code R156-11a-611 permits a master esthetician to use a microneedling device unsupervised where penetration does not exceed 1.5 mm, and requires general supervision by a licensed health care practitioner above it |
| Delegated medical act | Dermal microneedling is the practice of medicine, performed under physician or advanced-practice delegation with a good-faith examination | Virginia, where the Board for Barbers and Cosmetology guidance places microneedling beyond the scope of its licensees |
Florida’s rule text is the most quotable of the four because it names the numbers. Defining microneedling as creating microchannels 0.25 to 2.5 mm deep puts the regulatory line inside the dermis by arithmetic, which is exactly where the clinical and the legal questions turn out to be the same question.
Radiofrequency microneedling sits above all four tiers in most states, since the device adds a thermal element and an energy-device rule on top of the penetration rule. The trial at the top of this article used radiofrequency microneedling, which is worth noting when reading its protocol against a local scope rule.
Verify before you rely on any tier
Board positions move, and several states have revised microneedling language since 2021. Confirm the current rule with the state cosmetology or barbering board, the medical board and the nursing board before setting a protocol, and keep the citation with the protocol document. The rule citations in this article are listed in full in the sources below so they can be checked directly rather than taken on trust.
A precision applicator keeps the material where the workflow intends it
Once the depth decision belongs to the device, the remaining variable is what happens at the surface. Material applied by gloved hand, gauze or an open syringe tip spreads unevenly, and the quantity that reaches the treated field is difficult to describe afterward in a chart.
The CuraCator precision applicator is an FDA Class I sterile, single-use, needle-free Luer-lock applicator designed for controlled topical delivery of PRP, exosome material and serums after microneedling, radiofrequency and resurfacing procedures. It was developed by Dr. Janine Hopkins, a board-certified dermatologist who serves as an independent clinical advisor on procedural methodology.
The needle-free construction is the part that matters to everything above. An applicator with no needle adds no depth, so it cannot move a topical workflow across the dermal boundary the state rule and the clearance both describe.
- Luer-lock attachment to a standard syringe, so the preparation stays in a closed path from syringe to skin
- Single-use and sterile, packaged individually, which removes the cross-patient question from a step performed on open microchannels
- Needle-free, so the applicator contributes nothing to penetration depth and the depth record remains the device setting
- Controlled surface distribution, which makes the quantity applied to a field describable in the treatment record
ExaVeyra supplies the applicator to verified practices in boxes of twenty individually packaged units, with case quantities available. How it is used, with which material and on which patient are practitioner decisions, and the applicator’s clearance covers the applicator rather than anything applied through it.
Patient selection removes most of the risk before the device is switched on
The histories that change a facial microneedling decision are well described, and they divide into three groups: pigmentary conditions that the procedure itself can provoke, oncologic history that changes what should be done to a field at all, and the ordinary contraindications that apply to any procedure creating open channels.
Melasma needs the condition stable before the needling question opens
Microneedling has been studied in melasma rather than merely cautioned against. Wu, Muddasani and Alam published a systematic review of efficacy and safety in Dermatologic Surgery in 2020, and Simin and colleagues published a meta-analysis of randomised trials in Aesthetic Plastic Surgery in 2025.
Simin and colleagues concluded that microneedles show prospects as an assisted therapy in melasma while noting that no consensus on efficacy and safety has been reached. A meta-analysis that declines to declare consensus is reporting genuine heterogeneity in the trials rather than hedging.
The practical caution described across this literature concerns timing and control of the inflammatory load. Active worsening, recent sun exposure or tanning, an irritated barrier, a concurrent inflammatory eruption, and a plan that stacks several inflammatory procedures together are the conditions under which the pigmentary risk is highest.
A pigmentary history sets a more conservative margin
Cohen and Elbuluk reviewed microneedling in skin of color in the Journal of the American Academy of Dermatology in 2016, and Syder and Elbuluk reviewed radiofrequency microneedling in skin of color in Dermatologic Surgery in 2023. Both describe a procedure studied specifically in higher Fitzpatrick phototypes rather than extrapolated to them.
A documented history of marked post-inflammatory hyperpigmentation, keloid formation or poor wound healing is the finding that moves a patient into a more conservative plan: lower depth, longer intervals, a test area, and photoprotection established before the first session rather than after it.
A history of skin cancer belongs with the dermatologist before the aesthetic plan
A personal history of melanoma or keratinocyte carcinoma changes the facial field in two ways that an aesthetic consultation is not positioned to resolve. Previously treated sites carry scar and graft tissue with different thickness and vascularity, and a face under active surveillance is a face where new lesions are expected to be found.
An undiagnosed lesion in a treatment field is the specific concern. Needling across a lesion that has not been examined disrupts it and complicates later assessment, and pigmentary change induced by the procedure can obscure the visual features that surveillance depends on.
The route forward is a dermatologic clearance that addresses the field rather than the patient in general: which areas are under surveillance, which sites are post-treatment, and when the last full skin examination was performed. That document belongs in the chart before the consent conversation, and the decision that follows it is the treating clinician’s.
On cell-free preparations and oncologic history
Park and colleagues noted in their 2023 split-face study that tumorigenicity concerns, though rare, are among the reasons cell-free preparations drew interest as an alternative to mesenchymal stem cells themselves. Contreras and colleagues addressed safety and regulatory considerations for extracellular vesicles together in 2026. Neither paper establishes suitability for any patient, and oncologic history is a question for the treating clinician and the patient’s dermatologist.
The remaining screen is short and mostly procedural
- Active infection in the field, including herpes simplex, impetigo, folliculitis or inflammatory acne lesions, since open channels are created across the whole treated area
- Active inflammatory dermatoses in the field, such as eczema, psoriasis or rosacea in flare
- Recent isotretinoin exposure, where practice varies and the interval is a clinician decision
- Anticoagulant or antiplatelet therapy, bleeding disorders and thrombocytopenia, which bear on PRP specifically because the preparation depends on the patient’s own platelet function and yield
- Immunosuppression, poorly controlled diabetes and any condition that impairs wound healing
- Pregnancy and lactation, where the evidence base for either material is absent rather than reassuring
- Keloid or hypertrophic scar history
- Recent radiotherapy to the field
- Any undiagnosed lesion in the treatment area, which is examined before it is needled
Mashi and colleagues published a systematic review of microneedling for non-cosmetic dermatologic conditions in Cureus in 2025, which is a useful companion to the Gowda adverse-effects review when a practice is writing its own screening form.
What to settle before the first facial session
A facial programme that has answered the questions in this article has a short, checkable record behind it. The order below is the order in which each answer stops being reversible.
- The current rule from your state’s cosmetology, medical and nursing boards, cited in the protocol document, establishing who may hold the handpiece and to what depth
- A depth map by facial region, written against the anatomy rather than a single default setting, with the periorbita and other thin-skinned regions given their own numbers
- A written screen covering melasma activity, pigmentary history, oncologic history and the procedural contraindications, completed before consent
- A dermatologic clearance addressing the treatment field for any patient with a history of cutaneous malignancy
- For exosome material: the certificate of analysis, the characterisation panel, the cold-chain record and the available formats for the lot in hand
- For PRP: the kit, the spin protocol and the resulting preparation described consistently enough that two operators produce the same product
- A surface application step that is documented, with the applicator and quantity recorded alongside the device settings
The general comparison of the two materials outside a facial context is covered in the exosomes and PRP research comparison elsewhere on this site, and the applicator method is covered in the CuraCator clinical method article. Practices ready to source either material can verify an NPI and review current formats, certificates of analysis and cold-chain documentation directly.
Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, depth, device setting or protocol as safe, effective or appropriate for any patient. Exosome material referenced here is supplied for research use only; no exosome product is FDA-approved to diagnose, treat, cure or prevent any disease, and ExaVeyra Sciences makes no statement about administration, route or outcome. Findings described are attributed to the peer-reviewed literature and agencies cited, and a citation establishes that a question was studied rather than that a product suits a given patient. State scope-of-practice rules change; verify current requirements with the applicable state boards before adopting any protocol. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision or plan of care. Practitioners are responsible for compliance with all applicable state and federal regulations.
Peer-Reviewed References
- 1.Estupiñan B, Ly K, Goldberg DJ. Adipose mesenchymal stem cell-derived exosomes versus platelet-rich plasma treatment for photoaged facial skin: an investigator-blinded, split-face, non-inferiority trial. J Cosmet Dermatol. 2025;24(5):e70208. PMID 40414798
- 2.Park GH, Kwon HH, Seok J, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: a 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400
- 3.Chen H, Zhou X. Meta-analysis of the efficacy of platelet-rich plasma in treating skin aging. Aesthet Surg J Open Forum. 2026;8:ojaf150. PMID 41694325
- 4.Cruciani M, Masiello F, Pati I, et al. Platelet rich plasma for facial rejuvenation: an overview of systematic reviews. Blood Transfus. 2024;22(5):429-439. PMID 38557322
- 5.Rodríguez-Castro MJ, et al. Efficacy of platelet-rich plasma in facial rejuvenation: a systematic review. Enferm Clin (Engl Ed). 2025;35(5):502161. PMID 40118148
- 6.Sollitto CF, et al. A systematic review of platelet-rich plasma versus platelet-rich fibrin for periorbital rejuvenation. J Cosmet Dermatol. 2025;24(11):e70524. PMID 41190633
- 7.Alzahrani A, et al. Exosomes in skin rejuvenation: systematic review of anti-aging effects and clinical applications. Dermatol Pract Concept. 2026;16(1). PMID 41912205
- 8.Jafarzadeh A, et al. Effectiveness of regenerative medicine for skin lightening and rejuvenation: a systematic review of extracellular vesicles and conditioned media. Stem Cell Res Ther. 2025;16(1):513. PMID 41013717
- 9.Contreras C, et al. Extracellular vesicles in regenerative and cosmetic medicine: safety, clinical effectiveness, therapeutic applications, and regulatory considerations. Int J Mol Sci. 2026;27(12). PMID 42353255
- 10.AlBargawi S. Necrosis following dermal injection of lyophilized exosomes: a case report. J Cosmet Dermatol. 2025;24(8):e70387. PMID 40820962
- 11.Park KY. Adverse reactions following intradermal injection of exosome-based formulations: a case series. J Cosmet Dermatol. 2025;24(10):e70520. PMID 41097876
- 12.Chopra K, Calva D, Sosin M, et al. A comprehensive examination of topographic thickness of skin in the human face. Aesthet Surg J. 2015;35(8):1007-1013. PMID 26508650
- 13.Jeong KM, Seo JY, Kim A, et al. Ultrasonographic analysis of facial skin thickness in relation to age, site, sex, and body mass index. Skin Res Technol. 2023;29(8):e13426. PMID 37632182
- 14.Gowda A, Healey B, Ezaldein H, Merati M. A systematic review examining the potential adverse effects of microneedling. J Clin Aesthet Dermatol. 2021;14(1):45-54. PMID 33584968
- 15.Simin H, et al. Efficacy of microneedle as an assisted therapy for melasma: a meta-analysis and systematic review of randomized controlled trials. Aesthetic Plast Surg. 2025;49(6):1755-1769. PMID 39414648
- 16.Wu SZ, Muddasani S, Alam M. A systematic review of the efficacy and safety of microneedling in the treatment of melasma. Dermatol Surg. 2020;46(12):1636-1641. PMID 32897944
- 17.Cohen BE, Elbuluk N. Microneedling in skin of color: a review of uses and efficacy. J Am Acad Dermatol. 2016;74(2):348-355. PMID 26549251
- 18.Syder NC, Elbuluk N. Radiofrequency and radiofrequency microneedling in skin of color: a review of usage, safety, and efficacy. Dermatol Surg. 2023;49(5):489-493. PMID 36826381
- 19.Mashi A, et al. Microneedling for non-cosmetic dermatologic conditions: a systematic review of efficacy and safety. Cureus. 2025;17(8):e90857. PMID 40995236
- 20.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019. fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products
- 21.U.S. Food and Drug Administration. Regulatory Considerations for Microneedling Products: Guidance for Industry and FDA Staff. November 2020. Docket FDA-2017-D-4792. fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-microneedling-products
- 22.21 CFR 878.4430, Microneedling device for aesthetic use. Class II, FDA product code QAI. accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=878.4430
- 23.U.S. Food and Drug Administration. Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception. fda.gov/media/89920/download
- 24.U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. fda.gov/media/109176/download
- 25.Florida Administrative Code Rule 61G5-18.00015, Cosmetologist and Compensation Defined. Board of Cosmetology, effective 20 October 2021. flrules.org/gateway/RuleNo.asp?ID=61G5-18.00015
- 26.Utah Administrative Code R156-11a-611, Standards for Approval of Mechanical or Electrical Apparatus. Division of Professional Licensing. rules.utah.gov/publicat/code/r156/r156-11a.htm
- 27.Virginia Administrative Code 18VAC41-70-250, Scope of Practice; Virginia Board for Barbers and Cosmetology guidance document, License Required for Certain Procedures. law.lis.virginia.gov/admincode/title18/agency41/chapter70/section250